David W. Dube
Presidente en Stock Car Stocks Mutual Fund, Inc. .
Perfil
Mr. David W.
Dube, CPA, is a Director at Glycogenesys, Inc., President at Stock Car Stocks Mutual Fund, Inc., and Chairman & Chief Financial Officer at Swan Group of Cos., Inc. He is on the Board of Directors at Glycogenesys, Inc.
Mr. Dube also served on the board at CNE Group, Inc.
He received his undergraduate degree from Suffolk University, a graduate degree from Suffolk University, and a graduate degree from Bentley University.
Cargos activos de David W. Dube
Empresas | Cargo | Inicio |
---|---|---|
Stock Car Stocks Mutual Fund, Inc. | Presidente | 23/12/2009 |
Antiguos cargos conocidos de David W. Dube.
Empresas | Cargo | Fin |
---|---|---|
CNE Group, Inc. | Director/Miembro de la Junta | 14/11/2005 |
SWAN GROUP OF COMPANIES, INC. | Presidente | - |
Glycogenesys, Inc.
Glycogenesys, Inc. Miscellaneous Commercial ServicesCommercial Services GlycoGenesys, Inc., a biotechnology company, develops novel pharmaceutical products based on carbohydrate compounds and related technologies. The company's lead drug candidate GCS-100, a treatment for various forms of solid tumors and bloodborne cancers, completed a Phase II (a) clinical trial for pancreatic cancer, and also completed a Phase II (a) clinical trial for colorectal cancer. The company focuses on the development of carbohydrate-based pharmaceutical products and related technologies in connection with oncology. It was founded in 1992 and is headquartered in Boston, MA. | Director/Miembro de la Junta | - |
Formación de David W. Dube.
Suffolk University | Graduate Degree |
Bentley University | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 4 |
---|---|
CNE Group, Inc. | Commercial Services |
Glycogenesys, Inc.
Glycogenesys, Inc. Miscellaneous Commercial ServicesCommercial Services GlycoGenesys, Inc., a biotechnology company, develops novel pharmaceutical products based on carbohydrate compounds and related technologies. The company's lead drug candidate GCS-100, a treatment for various forms of solid tumors and bloodborne cancers, completed a Phase II (a) clinical trial for pancreatic cancer, and also completed a Phase II (a) clinical trial for colorectal cancer. The company focuses on the development of carbohydrate-based pharmaceutical products and related technologies in connection with oncology. It was founded in 1992 and is headquartered in Boston, MA. | Commercial Services |
Stock Car Stocks Mutual Fund, Inc. | Miscellaneous |
Swan Group of Cos., Inc.
Swan Group of Cos., Inc. Wholesale DistributorsDistribution Services Swan Group of Companies, Inc. engages in the manufacture and sale of smokeless cigarette products. The company was founded on January 24, 1996 and is headquartered in Largo, FL. | Distribution Services |
- Bolsa de valores
- Insiders
- David W. Dube